264 related articles for article (PubMed ID: 33889834)
21. Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy.
Hu CC; Weng CH; Chang LC; Lin CL; Chen YT; Hu CF; Hua MC; Chen LW; Chien RN
Ther Clin Risk Manag; 2018; 14():783-791. PubMed ID: 29750037
[TBL] [Abstract][Full Text] [Related]
22. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
[TBL] [Abstract][Full Text] [Related]
23. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
Kumada T; Toyoda H; Yasuda S; Ito T; Tsuji K; Fujioka S; Hiraoka A; Kariyama K; Nouso K; Ishikawa T; Tamai T; Tada T; Tanaka J
J Viral Hepat; 2022 Oct; 29(10):919-929. PubMed ID: 35790055
[TBL] [Abstract][Full Text] [Related]
24. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study.
Ciancio A; Ribaldone DG; Spertino M; Risso A; Ferrarotti D; Caviglia GP; Carucci P; Gaia S; Rolle E; Sacco M; Saracco GM
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672675
[TBL] [Abstract][Full Text] [Related]
25. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.
Lim N; Singh D; Jackson S; Lake JR
Gastrointest Tumors; 2020 Oct; 7(4):134-143. PubMed ID: 33173777
[TBL] [Abstract][Full Text] [Related]
26. Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study.
Tao XM; Zeng MH; Zhao YF; Han JX; Mi YQ; Xu L
World J Hepatol; 2024 Jan; 16(1):41-53. PubMed ID: 38313240
[TBL] [Abstract][Full Text] [Related]
27. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis.
Yongpisarn T; Thimphitthaya C; Laoveeravat P; Wongjarupong N; Chaiteerakij R
World J Hepatol; 2021 Aug; 13(8):949-968. PubMed ID: 34552701
[TBL] [Abstract][Full Text] [Related]
28. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Nozaki Y; Oshita M; Hiramatsu N; Miyazaki M; Mita E; Yamamoto K; Ohkawa K; Kaneko A; Ito T; Doi Y; Yakushijin T; Hijioka T; Fukui H; Imanaka K; Yoshida Y; Yamada Y; Tatsumi T; Takehara T
Hepatol Res; 2022 Oct; 52(10):824-832. PubMed ID: 35749289
[TBL] [Abstract][Full Text] [Related]
29. Frequency of
Rasool S; Hanif S; Ahmad A; Shafqat U; Babar AN
Euroasian J Hepatogastroenterol; 2022; 12(2):73-76. PubMed ID: 36959987
[TBL] [Abstract][Full Text] [Related]
30. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.
Puri P; Saraswat VA; Dhiman RK; Anand AC; Acharya SK; Singh SP; Chawla YK; Amarapurkar DN; Kumar A; Arora A; Dixit VK; Koshy A; Sood A; Duseja A; Kapoor D; Madan K; Srivastava A; Kumar A; Wadhawan M; Goel A; Verma A; Shalimar ; Pandey G; Malik R; Agrawal S
J Clin Exp Hepatol; 2016 Jun; 6(2):119-45. PubMed ID: 27493460
[TBL] [Abstract][Full Text] [Related]
31. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals.
Minami T; Tateishi R; Fujiwara N; Nakagomi R; Nakatsuka T; Sato M; Uchino K; Enooku K; Nakagawa H; Fujinaga H; Izumiya M; Hanajiri K; Asaoka Y; Kondo Y; Tanaka Y; Otsuka M; Ohki T; Arai M; Tanaka A; Yasuda K; Miura H; Ogata I; Kamoshida T; Inoue K; Koike Y; Akamatsu M; Mitsui H; Fujie H; Ogura K; Yoshida H; Wada T; Kurai K; Maekawa H; Obi S; Teratani T; Masaki N; Nagashima K; Ishikawa T; Kato N; Moriya K; Yotsuyanagi H; Koike K
Liver Cancer; 2021 Jul; 10(4):309-319. PubMed ID: 34414119
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance.
Tada T; Kumada T; Matono T; Nakamura S; Sue M; Matsuo Y; Takatani M; Iijima H; Tanaka J
JGH Open; 2022 Jul; 6(7):462-469. PubMed ID: 35822120
[TBL] [Abstract][Full Text] [Related]
33. Advances in the Era of Direct-Acting Antivirals for Hepatitis C in Patients with Unresectable Hepatocellular Carcinoma.
Chen LS; Lee SW; Yang SS; Tsai HJ; Lee TY
Dig Dis; 2022; 40(5):616-624. PubMed ID: 34753149
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals.
Lee HW; Han DH; Shin HJ; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217965
[TBL] [Abstract][Full Text] [Related]
35. A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kurosaki M; Tamaki N; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Nakamura S; Izumi N
JGH Open; 2022 Jan; 6(1):20-28. PubMed ID: 35071784
[TBL] [Abstract][Full Text] [Related]
36. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
Anand AC
J Clin Exp Hepatol; 2017 Mar; 7(1):42-54. PubMed ID: 28348470
[TBL] [Abstract][Full Text] [Related]
37. Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients.
Nirei K; Kanda T; Masuzaki R; Mizutani T; Moriyama M
Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440967
[No Abstract] [Full Text] [Related]
38. Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C.
Chen SH; Lai HC; Su WP; Kao JT; Chuang PH; Hsu WF; Wang HW; Hsieh TL; Chen HY; Peng CY
Can J Gastroenterol Hepatol; 2022; 2022():5201443. PubMed ID: 35837486
[TBL] [Abstract][Full Text] [Related]
39. No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.
Korenaga M; Murata K; Izumi N; Tamaki N; Yokosuka O; Takehara T; Sakamoto N; Suda G; Nishiguchi S; Enomoto H; Ikeda F; Yanase M; Toyoda H; Genda T; Umemura T; Yatsuhashi H; Yamasaki K; Ide T; Toda N; Kanda T; Nirei K; Ueno Y; Haga H; Nishigaki Y; Nakane K; Omata M; Mochizuki H; Aoki Y; Imamura M; Kanto T; Mizokami M
Glob Health Med; 2022 Aug; 4(4):216-224. PubMed ID: 36119787
[TBL] [Abstract][Full Text] [Related]
40. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.
Hagiwara H; Ito Y; Ohta T; Nozaki Y; Iwamoto T; Hosui A; Hiramatsu N; Tahata Y; Sakamori R; Hikita H; Hayashi N
JGH Open; 2022 Jun; 6(6):395-401. PubMed ID: 35774345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
